ImmuCell Long Term Investments vs Capital Stock Analysis
ICCC Stock | USD 3.70 0.04 1.07% |
ImmuCell financial indicator trend analysis is infinitely more than just investigating ImmuCell recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ImmuCell is a good investment. Please check the relationship between ImmuCell Long Term Investments and its Capital Stock accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuCell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.
Long Term Investments vs Capital Stock
Long Term Investments vs Capital Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ImmuCell Long Term Investments account and Capital Stock. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between ImmuCell's Long Term Investments and Capital Stock is -0.62. Overlapping area represents the amount of variation of Long Term Investments that can explain the historical movement of Capital Stock in the same time period over historical financial statements of ImmuCell, assuming nothing else is changed. The correlation between historical values of ImmuCell's Long Term Investments and Capital Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Investments of ImmuCell are associated (or correlated) with its Capital Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Stock has no effect on the direction of Long Term Investments i.e., ImmuCell's Long Term Investments and Capital Stock go up and down completely randomly.
Correlation Coefficient | -0.62 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Long Term Investments
Long Term Investments is an item on the asset side of ImmuCell balance sheet that represents investments ImmuCell intends to hold for over a year. ImmuCell long term investments may include different instruments such as stocks, bonds, real estate and cash.Capital Stock
The total amount of a company's capital funded by shareholders through the issue and subscription of shares.Most indicators from ImmuCell's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ImmuCell current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuCell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.At present, ImmuCell's Enterprise Value is projected to increase significantly based on the last few years of reporting.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 8.7M | 7.6M | 4.4M | 3.9M | Total Revenue | 19.2M | 18.6M | 17.5M | 18.3M |
ImmuCell fundamental ratios Correlations
Click cells to compare fundamentals
ImmuCell Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ImmuCell fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 38.7M | 40.4M | 44.5M | 44.9M | 43.8M | 46.0M | |
Short Long Term Debt Total | 8.4M | 10.7M | 10.3M | 12.5M | 16.7M | 17.5M | |
Other Current Liab | 648.4K | 747.9K | 867.1K | 1.2M | 956.2K | 1.0M | |
Total Current Liabilities | 2.5M | 2.2M | 2.5M | 3.1M | 4.2M | 4.4M | |
Total Stockholder Equity | 29.0M | 28.3M | 32.6M | 30.4M | 25.0M | 26.2M | |
Property Plant And Equipment Net | 25.3M | 28.0M | 28.0M | 30.6M | 32.1M | 33.8M | |
Net Debt | (352.5K) | 2.8M | 89.0K | 6.7M | 15.7M | 16.5M | |
Retained Earnings | (2.6M) | (3.7M) | (3.7M) | (6.2M) | (12.0M) | (11.4M) | |
Cash | 8.8M | 7.9M | 10.2M | 5.8M | 978.7K | 929.8K | |
Non Current Assets Total | 25.5M | 28.2M | 28.2M | 30.9M | 32.3M | 34.0M | |
Non Currrent Assets Other | 26.9K | 26.2K | 26.1K | 76.6K | 57.7K | 54.8K | |
Cash And Short Term Investments | 8.8M | 7.9M | 10.2M | 5.8M | 978.7K | 929.8K | |
Net Receivables | 1.7M | 1.9M | 2.7M | 1.8M | 2.2M | 2.3M | |
Common Stock Shares Outstanding | 6.8M | 7.2M | 7.6M | 7.7M | 7.7M | 3.9M | |
Liabilities And Stockholders Equity | 38.7M | 40.4M | 44.5M | 44.9M | 43.8M | 46.0M | |
Non Current Liabilities Total | 7.2M | 9.9M | 9.4M | 11.4M | 14.6M | 15.2M | |
Inventory | 2.5M | 2.1M | 3.1M | 6.0M | 7.8M | 8.2M | |
Other Current Assets | 219.1K | 253.6K | 268.7K | 363.9K | 493.9K | 247.6K | |
Other Stockholder Equity | 30.9M | 31.2M | 35.5M | 35.8M | 36.2M | 38.0M | |
Total Liab | 9.7M | 12.1M | 11.9M | 14.5M | 18.8M | 19.8M | |
Total Current Assets | 13.2M | 12.2M | 16.3M | 14.0M | 11.5M | 7.0M | |
Short Term Debt | 1.3M | 860.8K | 920.2K | 1.1M | 2.1M | 2.0M | |
Intangible Assets | 114.6K | 95.5K | 76.4K | 57.3K | 38.2K | 36.3K | |
Accounts Payable | 572.2K | 602.3K | 745.0K | 790.0K | 874.6K | 918.3K | |
Property Plant And Equipment Gross | 25.3M | 26.8M | 42.0M | 46.5M | 53.5M | 56.2M | |
Other Assets | 164.0 | 406.0 | 312.0 | 351.0 | 1.0 | 0.95 | |
Long Term Debt | 7.1M | 8.7M | 8.3M | 9.2M | 10.6M | 11.1M | |
Treasury Stock | (407.9K) | (204.9K) | (188.3K) | (175.4K) | (201.7K) | (211.8K) | |
Property Plant Equipment | 25.3M | 28.0M | 28.0M | 30.6B | 35.2B | 37.0B | |
Net Tangible Assets | 28.8M | 27.8M | 32.3M | 30.2B | 34.8B | 36.5B | |
Retained Earnings Total Equity | 979.0K | (1.3M) | (2.6M) | (3.7M) | (3.3M) | (3.1M) | |
Long Term Debt Total | 8.6M | 8.4M | 7.1M | 8.7M | 10.0M | 10.6M | |
Capital Surpluse | 22.5M | 22.7M | 31.1M | 31.4M | 36.1M | 19.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ImmuCell offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ImmuCell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immucell Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immucell Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuCell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmuCell. If investors know ImmuCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmuCell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.63) | Earnings Share (0.49) | Revenue Per Share 2.991 | Quarterly Revenue Growth 0.549 | Return On Assets (0.05) |
The market value of ImmuCell is measured differently than its book value, which is the value of ImmuCell that is recorded on the company's balance sheet. Investors also form their own opinion of ImmuCell's value that differs from its market value or its book value, called intrinsic value, which is ImmuCell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmuCell's market value can be influenced by many factors that don't directly affect ImmuCell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmuCell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.